Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A197 in Dry Eye Disease
NCT05238597Phase 2Completed
- Sponsor
- Aramis Biosciences
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of A197 in dry eye disease (DED) (4 arms), sponsored by Aramis Biosciences. Primary endpoint: Change from baseline in total corneal fluorescein staining at 12 weeks. Started Jan 2022; status: completed.
02
Drugs
A197
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05238597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238597.